Verwendung: Dieses Produkt ist ausschließlich für Forschungszwecke bestimmt.
Alle Produktinformationen auf dieser Website dienen ausschließlich Bildungszwecken. Jede Form der Einbringung in den Körper von Menschen oder Tieren ist gesetzlich streng verboten. Dieses Produkt darf nur von zugelassenen und qualifizierten Fachleuten gehandhabt werden. Es ist kein Arzneimittel, Lebensmittel oder Kosmetikum und darf nicht als solches gekennzeichnet, verwendet oder falsch etikettiert werden.
Noopept (Omberacetam), (30mg/capsule), 60 Capsules
Während der Umstellung unserer Verpackung erhalten Sie möglicherweise Produkte mit dem bisherigen oder dem neuen Etikett. Formulierung, Reinheit und Qualität bleiben nach unseren Standards genau gleich.
- Kreditkarte
- Banküberweisung (SEPA Echtzeit)
- Banküberweisung (ACH)
- Wise
- Revolut
- Zelle
- Remitly
- Western Union
- Chime
- Andere
-25% auf alles – bis 31. Oktober
25% auf reguläre Preise statt anderer Angebote. Nur mit dem Krypto-Zahlungsrabatt kombinierbar.
Jede Charge wird auf Reinheit, Wirksamkeit und Qualität geprüft.
Laborergebnisse ansehen →Noopept (Omberacetam) is a synthetic dipeptide analog of the racetam family, known for its role in glutamatergic and cholinergic signaling pathways. It exhibits high affinity for AMPA and NMDA receptors, contributing to its involvement in synaptic transmission and neurochemical interactions.
This compound undergoes rapid hydrolysis into bioactive peptide fragments, facilitating its metabolic activity. Noopept is processed through hepatic oxidation and conjugation, with primary clearance occurring via renal excretion.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom
What is cycloprolylglycine and why is Noopept considered its prodrug?
Cycloprolylglycine (cPG) is a cyclic dipeptide investigated in studies of peptide-mediated signaling systems and receptor-associated regulatory pathways. Noopept undergoes biotransformation to yield cPG as a principal metabolite, making it a useful research tool for examining prodrug conversion mechanisms, metabolite-associated pharmacology, and the relationship between parent compounds and biologically active peptide derivatives. This prodrug relationship distinguishes Noopept from compounds that act exclusively through direct receptor interactions.
How does Noopept differ from racetam-class compounds in pharmacology research?
Although frequently evaluated alongside racetam-class compounds, Noopept is structurally distinct as a dipeptide-derived molecule rather than a cyclic lactam. Experimental investigations have examined its interactions with glutamatergic signaling pathways, receptor-associated regulatory systems, and cycloprolylglycine-related mechanisms. These characteristics make Noopept a useful research tool for comparative studies involving small molecule–peptide pharmacology, prodrug metabolism, and receptor-mediated signaling processes.
What interactions between Noopept and protein aggregation systems have been investigated?
Experimental studies have examined Noopept in relation to protein aggregation pathways, molecular assembly processes, and protein-protein interaction systems. Investigations have explored its effects on aggregation dynamics, conformational stability, and structural organization within protein regulatory networks. These characteristics have contributed to its use in research involving molecular interaction pathways, protein assembly mechanisms, and structure-function relationship studies.
